Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MESRIX-II
- Development stage
- Unknown
- Lead developer
- Cell to Cure
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intraglandular
01
Overview
MESRIX-II is an investigational allogeneic cell therapy consisting of adipose-derived mesenchymal stromal cells (ASCs/MSCs). Developed by Cell to Cure (a portfolio company of Endeavour Cell), it is specifically designed to treat radiation-induced xerostomia (dry mouth) and hyposalivation in patients who have undergone radiotherapy for head and neck cancer. The therapy is administered via ultrasound-guided injection directly into the submandibular and parotid glands. Its mechanism of action is primarily attributed to paracrine and immunomodulatory effects, where the injected cells secrete bioactive factors that reduce inflammation, promote angiogenesis, and stimulate the repair of damaged salivary gland tissue. It is currently in Phase 2 clinical development.
- Other names
- ASC/MSCallogeneic adipose-derived mesenchymal stromal cell therapy
Beyond the preview
Go deeper on MESRIX-II.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MESRIX-II.